Article Text

Download PDFPDF

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy
  1. Matthias Preusser
  1. Medical University of Vienna, Department of Medicine I, Division of Oncology, Vienna, Austria
  1. Correspondence to Matthias Preusser; matthias.preusser{at}meduniwien.ac.at

Statistics from Altmetric.com

Immunotherapy has revolutionised medical oncology due to durable responses and favourable clinical trial outcomes seen in some patient populations treated with immune checkpoint inhibitors.1 As a consequence, various immune checkpoint inhibitors have been approved by regulatory bodies and have quickly been adpoted as the standard treatment option in several cancer types, such as melanoma, lung cancer and renal cell cancer.2–8 Efficacy has been shown not only in metastatic stages including patients in highly advanced treatment phases but also in patients with lung cancer and melanoma treated in the adjuvant setting.9 Recent data from lung cancer, …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.